A Phase 2 interventional study of AD-211-L and AD-211-M in Osteoarthritis of the Knees, sponsored by Addpharma Inc.. Not yet recruiting. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the optimal dose of AD-211 in patients with osteoarthritis of the knee.
Osteoarthritis of the knee
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
This study's planned enrollment of 200 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Browse Osteoarthritis, Knee studies →Addpharma Inc. is the lead sponsor of 58 studies on the registry; 25 are open to participants now.
First submitted after Addpharma Inc. became part of Yuhan Corporation.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 Week: twice daily; 2 tablets per dose (AD-211-L + placebo to AD-2113). 12 Weeks: twice daily; 3 tablets per dose (AD-211-L + placebo to AD-211-H + placebo to AD-2113).
Drug: AD-211-L · Drug: Placebo to AD-211-H · Drug: Placebo to AD-2113
1 Week: twice daily; 2 tablets per dose AD-211-M + placebo to AD-2113). 12 Weeks: twice daily; 3 tablets per dose (AD-211-M + placebo to AD-211-H + placebo to AD-2113).
Drug: AD-211-M · Drug: Placebo to AD-211-H · Drug: Placebo to AD-2113
1 Week: twice daily; 2 tablets per dose (AD-211-M + placebo to AD-2113). 12 Weeks: twice daily; 3 tablets per dose (AD-211-H + placebo to AD-211-L/M + placebo to AD-2113).
Drug: AD-211-M · Drug: AD-211-H · Drug: Placebo to AD-211-L/M · Drug: Placebo to AD-2113
1 Week: twice daily; 2 tablets per dose (AD-2113 + placebo to AD-211-L/M). 12 Weeks: twice daily; 3 tablets per dose (AD-2113 + placebo to AD-211-L/M + placebo to AD-211-H).
Drug: AD-2113 · Drug: Placebo to AD-211-L/M · Drug: Placebo to AD-211-H
Per oral, 1 tablet twice daily during the treatment period.
Per oral, 1 tablet twice daily during the treatment period.
Per oral, 1 tablet twice daily during the treatment period.
Per oral, 1 tablet twice daily during the treatment period.
Per oral, 1 tablet twice daily during the treatment period.
Per oral, 1 tablet twice daily during the treatment period.
Per oral, 1 tablet twice daily during the treatment period.
Change from baseline in 100 mm Pain VAS score during activity over the past 24 hours in the target knee
Time frame: Baseline to Week13
No study locations are listed for this record.
Start is estimated for Jun 2026; primary completion for Mar 2027, 9 months later.
Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's planned 9 months is below that.
Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.